Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.71 |
| ▸ | NR4A2 | P43354 | 6/20 | 0.61 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.57 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.56 |
| ▸ | PRSS1 | P07477 | 4/20 | 0.56 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.55 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9803295 | 0.93 | KMT2A (0.80) | KMT2ANR4A2PLA2G4BNPC1RAB9A | |
| SCHEMBL4509654 | 0.91 | KMT2A (0.77) | KMT2ANR4A2PLA2G4BNR1H4AKR1C3 | |
| SCHEMBL30167982 | 0.89 | KMT2A (0.80) | KMT2ANR4A2PLA2G4BNPC1RAB9A | |
| SCHEMBL10787479 | 0.89 | KMT2A (0.80) | KMT2ANR4A2PLA2G4BNPC1RAB9A | |
| SCHEMBL9402647 | 0.88 | KMT2A (0.73) | KMT2ANR4A2PLA2G4BNPC1RAB9A | |
| SCHEMBL4724803 | 0.86 | NR4A2 (0.65) | KMT2ANR4A2NPC1RAB9ANR1H4 | |
| SCHEMBL6932542 | 0.86 | KMT2A (0.75) | KMT2ANR4A2PLA2G4BNPC1RAB9A | |
| SCHEMBL8733167 | 0.85 | KMT2A (0.69) | KMT2ANR4A2PLA2G4BNPC1RAB9A | |
| SCHEMBL4799598 | 0.85 | KMT2A (0.69) | KMT2ANR4A2PLA2G4BNR1H4AKR1C3 | |
| SCHEMBL2455314 | 0.85 | KMT2A (0.84) | KMT2APLA2G4BNR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109563045-B | Pd (II) -catalysed enantioselective beta-methylene C (sp) 3 ) -H bond activation | 斯克里普斯研究学院 | 2022-08-23 | — | — | CN | disclosed |
| US-11186563-B2 | Pd(II)-catalyzed enantioselective β-methylene C(sp3)—H bond activation | THE SCRIPPS RESEARCH INSTITUTE (US) | 2021-11-30 | — | — | US | disclosed |
| US-20190315710-A1 | Pd(II)-catalyzed Enantioselective Beta-Methylene C(sp3)–H Bond Activation | THE SCRIPPS RESEARCH INSTITUTE | 2019-10-17 | — | — | US | disclosed |
| EP-3440056-A2 | PD(II)-CATALYZED ENANTIOSELECTIVE BETA-METHYLENE C(SP3)-H BOND ACTIVATION | The Scripps Research Institute (US) | 2019-02-13 | — | — | EP | disclosed |
| WO-2017165304-A2 | Pd(II)-CATALYZED ENANTIOSELECTIVE BETA-METHYLENE C(sp3)-H BOND ACTIVATION | THE SCRIPPS RESEARCH INSTITUTE (US) | 2017-09-28 | — | — | WO | disclosed |
| US-5278133-A | Benzyl pyridones antigrowth agent | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1994-01-11 | — | — | US | disclosed |
| US-5260261-A | Fused pyridine herbicides | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190315710-A1 | Pd(II)-catalyzed Enantioselective Beta-Methylene C(sp3)–H Bond Activation | POLQ, AP3D1, AP3S1 | KMT2A 787/4885NR4A2 3092/4885PLA2G4B 4096/4885 |
| US-11186563-B2 | Pd(II)-catalyzed enantioselective β-methylene C(sp3)—H bond activation | POLQ, AP3D1, AP3S1 | KMT2A 666/4885NR4A2 3106/4885PLA2G4B 4214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.